NDATOPICALGEL
Approved
Jun 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
DIFFERIN (adapalene) by Galderma is protein. Approved for acne vulgaris, photoaging. First approved in 2007.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIFFERIN (adapalene) is a topical retinoid gel approved for acne vulgaris and indicated for photoaging, photodamage, and acne scars. It modulates cellular differentiation, keratinization, and inflammatory processes through an incompletely understood mechanism of action.
$0.094MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D spending; brand team likely focused on life-cycle extension and market defense rather than growth.
Mechanism of Action
protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne…
Pharmacologic Class:
Retinoid
Indications (2)
Worked on DIFFERIN at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.